The joint stock company “Grindeks” shareholders’ annual general meeting held on June 26, 2018 decides on distribution of the profit for the year 2017 to set September 11, 2018 as the date of calculation of dividends. Therefore, September 10, 2018 is the ex-date, from that date the new owner of the shares is not entitled to dividends for the year 2017.
The dividend in amount of EUR 0.15 (fifteen cents) per one share payment date of joint stock company “Grindeks” is September 12, 2018.
“Grindeks” is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” has four subsidiary companies in Latvia, Estonia, and Slovakia as well as representative offices in 11 countries.
“Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics, food supplements and active pharmaceutical ingredients.
In 2017, products of the company were exported to 77 countries with export comprising 92.5% of the total turnover. The key markets include the EU countries, Russia and the other CIS countries, the U.S., Canada, Japan and Vietnam.
To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing around 100 million euros over the last 15 years.
*Notice: meldonium is included in the list of substances prohibited in sport.
Public Relations Specialist
Phones: (+371) 67083336
Fax: (+371) 67083505